Abstract
Objectives
Medication-induced salivary gland dysfunction (MISGD) causes significant morbidity resulting in decreased quality of life. This systematic review assessed the literature on the prevalence, diagnosis, treatment, and prevention of MISGD.
Materials and methods
Electronic databases were searched for articles related to MISGD through June 2013. Four independent reviewers extracted information regarding study design, study population, interventions, outcomes, and conclusions for each article. Only papers with acceptable degree of relevance, quality of methodology, and strength of evidence were retained for further analysis.
Results
There were limited data on the epidemiology of MISGD. Furthermore, various methods were used to assess salivary flow rate or xerostomia. Preventive and therapeutic strategies included substitution of medications, oral, or systemic therapy with sialogogues, use of saliva substitutes or of electro-stimulating devices. Although there are promising approaches to improve salivary gland function, most studies are characterized by small numbers and heterogeneous methods.
Conclusions
Physicians and dentists should identify the medications associated with xerostomia and salivary gland dysfunction through a thorough medical history. Preferably, health care providers should measure the unstimulated and stimulated whole salivary flow rates of all their patients so that these values can be used as a baseline to rate the complaints of patients who subsequently claim to experience xerostomia or salivary gland dysfunction as well as the possibilities of effectively treating this condition.
Clinical relevance
MISGD remains a major burden for the population. This systematic review provides a contemporary in-depth description of the diagnosis and treatment of MISGD.
Similar content being viewed by others
References
Ekström J, Khosravani N, Castagnola M, Messana I (2012) Saliva and the control of its secretion. In: Ekberg O (ed) Dysphagia: diagnosis and treatment. Springer, Berlin, pp 19–47
Watanabe S, Dawes C (1988) The effects of different foods and concentrations of citric acid on the flow rate of whole saliva in man. Arch Oral Biol 33(1):1–5
Humphrey SP, Williamson RT (2001) A review of saliva: normal composition, flow, and function. J Prosthet Dent 85(2):162–169
Pedersen AM, Bardow A, Jensen SB, Nauntofte B (2002) Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis 8(3):117–129
Edgar M, Dawes C, O'Mullane D (2012) Saliva and oral health. 4th ed. Stephen Hancocks Ltd, London, pp 1–154
Potulska A, Friedman A (2005) Controlling sialorrhoea: a review of available treatment options. Expert Opin Pharmacother 6(9):1551–1554
Sreebny L, Vissink A (2010) Dry mouth: the malevolent symptom. In: Sreebny LM, Vissink A (eds) A clinical guide. Wiley-Blackwell, Ames, USA
Guggenheimer J, Moore PA (2003) Xerostomia: etiology, recognition and treatment. J Am Dent Assoc 134(1):61–69, quiz 118-119
Atkinson JC, Wu AJ (1994) Salivary gland dysfunction: causes, symptoms, treatment. J Am Dent Assoc 125(4):409–416
Fischer D, Ship JA (1997) The effect of dehydration on parotid salivary gland function. Spec Care Dentist 17(2):58–64
Heintze U, Birkhed D, Björn H (1983) Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J 7(6):227–238
Dawes C (1987) Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 66(Spec No):648–653
van der Putten GJ, Brand HS, Schols JM, de Baat C (2011) The diagnostic suitability of a xerostomia questionnaire and the association between xerostomia, hyposalivation and medication use in a group of nursing home residents. Clin Oral Investig 15(2):185–192
Dawes C (2004) How much saliva is enough for avoidance of xerostomia? Caries Res 38(3):236–240
Nagler RM (2004) Salivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoring. Biogerontology 5(4):223–233
Bergdahl M, Bergdahl J (2000) Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 79(9):1652–1658
Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM (2010) Associations between labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. Community Dent Oral Epidemiol 38(5):422–435
Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM (2011) Associations between oral and ocular dryness, labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. Community Dent Oral Epidemiol 39(3):276–288
Leal SC, Bittar J, Portugal A, Falcao DP, Faber J, Zanotta P (2010) Medication in elderly people: its influence on salivary pattern, signs and symptoms of dry mouth. Gerodontology 27(2):129–133
Moore PA, Guggenheimer J (2008) Medication-induced hyposalivation: etiology, diagnosis, and treatment. Compend Contin Educ Dent 29(1):50–55
Baccaglini L, Brennan MT, Lockhart PB, Patton LL (2007) World Workshop on Oral Medicine IV: process and methodology for systematic review and developing management recommendations. Reference manual for management recommendations writing committees. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103(Suppl:S3):e1–e19
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7), e1000097
Liu B, Dion MR, Jurasic MM, Gibson G, Jones JA (2012) Xerostomia and salivary hypofunction in vulnerable elders: prevalence and etiology. Oral Surg Oral Med Oral Pathol Oral Radiol 114(1):52–60
Hopcraft MS, Tan C (2010) Xerostomia: an update for clinicians. Aust Dent J 55(3):238–244, quiz 353
Astor FC, Hanft KL, Ciocon JO (1999) Xerostomia: a prevalent condition in the elderly. Ear Nose Throat J 78(7):476–479
Locker D (1993) Subjective reports of oral dryness in an older adult population. Community Dent Oral Epidemiol 21(3):165–168
Thorselius I, Emilson CG, Osterberg T (1988) Salivary conditions and drug consumption in older age groups of elderly Swedish individuals. Gerodontics 4(2):66–70
Furness S, Bryan G, McMillan R, Birchenough S, Worthington HV (2013) Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 9, CD009603
Nederfors T, Isaksson R, Mornstad H, Dahlof C (1997) Prevalence of perceived symptoms of dry mouth in an adult Swedish population—relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 25(3):211–216
Villa A, Polimeni A, Strohmenger L, Cicciu D, Gherlone E, Abati S (2011) Dental patients' self-reports of xerostomia and associated risk factors. J Am Dent Assoc 142(7):811–816
Murray Thomson W, Poulton R, Mark Broadbent J, Al-Kubaisy S (2006) Xerostomia and medications among 32-year-olds. Acta Odontol Scand 64(4):249–254
Habbab KM, Moles DR, Porter SR (2010) Potential oral manifestations of cardiovascular drugs. Oral Dis 16(8):769–773
Hasan SS, Keong SC, Choong CL, Ahmed SI, Ching TW, Anwar M, Ahmadi K, Babar MG (2011) Patient-reported adverse drug reactions and drug-drug interactions: a cross-sectional study on Malaysian HIV/AIDS patients. Med Princ Pract 20(3):265–270
Nonzee V, Manopatanakul S, Khovidhunkit SO (2012) Xerostomia, hyposalivation and oral microbiota in patients using antihypertensive medications. J Med Assoc Thail 95(1):96–104
Hunter KD, Wilson WS (1995) The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 40(11):983–989
Thomson WM, Chalmers JM, Spencer JA, Slade GD, Carter KD (2006) A longitudinal study of medication exposure and xerostomia among older people. Gerodontology 23(4):205–213
Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300(24):2867–2878
Health and Social Care Information Centre. Prescriptions dispensed in the community, statistics for England, 2001-2011 (2012) Retrieved from: www.hscic.gov.uk/searchcatalogue?productid=7930&topics=0%2fPrescribing&pubdate=%2c2012&sort=Relevance&size=10&page=7#top
Guthrie B, Makubate B (2012) The rising tide of polypharmacy and potentially serious drug interactions 1995–2010: repeated cross sectional analysis of dispensed prescribing in one region. Prim Health Care Res Dev 13(1):45
Center for Disease Control and Prevention (2013) Retrieved from: www.cdc.gov/nchs/fastats/drugs.htm
Nederfors T (1996) Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. Swed Dent J Suppl 116:1–70
Turner MD, Ship JA (2007) Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc 138(Suppl):15S–20S
Valdez IH, Fox PC (1993) Diagnosis and management of salivary dysfunction. Crit Rev Oral Biol Med 4(3-4):271–277
Fox PC (1996) Differentiation of dry mouth etiology. Adv Dent Res 10(1):13–16
Fox PC, Busch KA, Baum BJ (1987) Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 115(4):581–584
Sreebny LM, Valdini A (1988) Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458
Thomson WM, Chalmers JM, Spencer AJ, Williams SM (1999) The xerostomia inventory: a multi-item approach to measuring dry mouth. Community Dent Health 16(1):12–17
Thomson WM, Chalmers JM, Spencer AJ, Slade GD (2000) Medication and dry mouth: findings from a cohort study of older people. J Public Health Dent 60(1):12–20
Pai S, Ghezzi EM, Ship JA (2001) Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91(3):311–316
Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, Scarantino C, Brizel D (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13(3):226–234
Radfar L, Masood F (2013) Review of sialadenosis for clinicians. J Okla Dent Assoc 104(5):32–33
Osailan S, Pramanik R, Shirodaria S, Challacombe SJ, Proctor GB (2011) Investigating the relationship between hyposalivation and mucosal wetness. Oral Dis 17(1):109–114
Krief G, Deutsch O, Zaks B, Wong DT, Aframian DJ, Palmon A (2012) Comparison of diverse affinity based high-abundance protein depletion strategies for improved bio-marker discovery in oral fluids. J Proteomics 75(13):4165–4175
Wu AJ, Ship JA (1993) A characterization of major salivary gland flow rates in the presence of medications and systemic diseases. Oral Surg Oral Med Oral Pathol 76(3):301–306
Löfgren CD, Wickstrom C, Sonesson M, Lagunas PT, Christersson C (2012) A systematic review of methods to diagnose oral dryness and salivary gland function. BMC Oral Health 12:29
Nederfors T (2000) Xerostomia and hyposalivation. Adv Dent Res 14:48–56
Navazesh M (1993) Methods for collecting saliva. Ann N Y Acad 694:72–77
van den Berg I, Pijpe J, Vissink A (2007) Salivary gland parameters and clinical data related to the underlying disorder in patients with persisting xerostomia. Eur J Oral Sci 115(2):97–102
Chen A, Wai Y, Lee L, Lake S, Woo SB (2005) Using the modified Schirmer test to measure mouth dryness: a preliminary study. J Am Dent Assoc 136(2):164–170, quiz 229-130
Navazesh M, Kumar SK, University of Southern California School of D (2008) Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 139(Suppl):35S–40S
Lashley KS (1916) Reflex secretion of the human parotid gland. J Exp Psychol 1(6):461–493
Schneyer LH (1955) Method for the collection of separate submaxillary and sublingual salivas in man. J Dent Res 34(2):257–261
Wolff A, Begleiter A, Moskona D (1997) A novel system of human submandibular/sublingual saliva collection. J Dent Res 76(11):1782–1786
Eliasson L, Carlen A (2010) An update on minor salivary gland secretions. Eur J Oral Sci 118(5):435–442
Jensen SB, Mouridsen HT, Reibel J, Brunner N, Nauntofte B (2008) Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncol 44(2):162–173
Bardow A, Nyvad B, Nauntofte B (2001) Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ. Arch Oral Biol 46(5):413–423
Vucicevic Boras V, Brailo V, Lukac J, Kordic D, Picek P, Blazic-Potocki Z (2006) Salivary interleukin-6 and tumor necrosis factor alpha in patients with drug-induced xerostomia. Oral Dis 12(5):509–511
Amado FM, Ferreira RP, Vitorino R (2013) One decade of salivary proteomics: current approaches and outstanding challenges. Clin Biochem 46(6):506–517
Fleissig Y, Deutsch O, Reichenberg E, Redlich M, Zaks B, Palmon A, Aframian DJ (2009) Different proteomic protein patterns in saliva of Sjögren's syndrome patients. Oral Dis 15
Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, Hu S, Arellano M, Sinha U, Le A, Messadi D, Wang M, Nabili V, Lingen M, Morris D, Randolph T, Feng Z, Akin D, Kastratovic DA, Chia D, Abemayor E, Wong DT (2012) Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev 21(4):664–672
Hu S, Gao K, Pollard R, Arellano-Garcia M, Zhou H, Zhang L, Elashoff D, Kallenberg CG, Vissink A, Wong DT (2010) Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res 62(11):1633–1638
Hu S, Vissink A, Arellano M, Roozendaal C, Zhou H, Kallenberg CG, Wong DT (2011) Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays. Proteomics 11(8):1499–1507
Hu S, Wang J, Meijer JM, Ieong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J, Kallenberg CG, Elashoff D, Loo JA, Wong DT (2007) Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 56(11):3588–3600
Kelentey B, Kerr M, Tao Z, Purushotham KR, Humphreys-Beher MG, Zelles T (1996) Inhibition of rat parotid gland growth response induced by chronic isoproterenol following treatment with quinolone antibiotics. Mol Cell Biochem 165(1):55–63
Bedi GS (1993) The effect of adrenergic agonists and antagonists on the expression of proteins in rat submandibular and parotid glands. Crit Rev Oral Biol Med 4(3-4):565–571
Schneyer CA (1986) Growth of rat salivary glands after terbutaline or dobutamine. J Oral Pathol 15(2):66–70
Waldeck B (2011) "The beta1-selective adrenoceptor agonist dobutamine": a fallacy being perpetuated. Chirality 23(1):63–64
Ekström J, Malmberg L (1984) Beta 1-adrenoceptor mediated salivary gland enlargement in the rat. Experientia 40(8):862–863
Bloom GD, Carlsoo B, Danielsson A, Gustafsson H, Henriksson R (1979) Quantitative structural analysis and the secretory behaviour of the rat parotid gland after long and short term isoprenaline treatment. Med Biol 57(4):224–233
Ohlin P, Perec C (1966) Effects of atropine treatment on the submaxillary gland of rats. Physiol Cogn Med Sci 51(3):196–201
Månsson B, Nilsson BO, Ekström J (1990) Effects of repeated infusions of substance P and vasoactive intestinal peptide on the weights of salivary glands subjected to atrophying influences in rats. Br J Pharmacol 101(4):853–858
Kaplan I, Zuk-Paz L, Wolff A (2008) Association between salivary flow rates, oral symptoms, and oral mucosal status. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106(2):235–241
Cho MA, Ko JY, Kim YK, Kho HS (2010) Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology. J Oral Rehabil 37(3):185–193
Visvanathan V, Nix P (2010) Managing the patient presenting with xerostomia: a review. Int J Clin Pract 64(3):404–407
Iwabuchi Y, Katagiri M, Masuhara T (1994) Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice. Arch Int Pharmacodyn Ther 328(3):315–325
Wiseman LR, Faulds D (1995) Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 49(1):143–155
Takakura AC, Moreira TS, Laitano SC, De Luca Junior LA, Renzi A, Menani JV (2003) Central muscarinic receptors signal pilocarpine-induced salivation. J Dent Res 82(12):993–997
Schneyer CA, Hall HD (1966) Autonomic pathways involved in a sympathetic-like action of pilocarpine on salivary composition. Proc Soc Exp Biol Med Soc Exp Biol Med 121(1):96–100
Chambers MS, Jones CU, Biel MA, Weber RS, Hodge KM, Chen Y, Holland JM, Ship JA, Vitti R, Armstrong I, Garden AS, Haddad R (2007) Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys 69(5):1369–1376
Iwabuchi Y, Masuhara T (1994) Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen's syndrome. Gen Pharmacol 25(1):123–129
Weber J, Keating GM (2008) Cevimeline. Drugs 68(12):1691–1698
Braga MA, Tarzia O, Bergamaschi CC, Santos FA, Andrade ED, Groppo FC (2009) Comparison of the effects of pilocarpine and cevimeline on salivary flow. Int J Dent Hyg 7(2):126–130
Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C (2007) Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis 13(1):88–92
Gomez-Moreno G, Aguilar-Salvatierra A, Guardia J, Uribe-Marioni A, Cabrera-Ayala M, Delgado-Ruiz RA, Calvo-Guirado JL (2013) The efficacy of a topical sialogogue spray containing 1% malic acid in patients with antidepressant-induced dry mouth: a double-blind, randomized clinical trial. Depress Anxiety 30(2):137–142
Gomez-Moreno G, Guardia J, Aguilar-Salvatierra A, Cabrera-Ayala M, Mate-Sanchez de-Val JE, Calvo-Guirado JL (2013) Effectiveness of malic acid 1% in patients with xerostomia induced by antihypertensive drugs. Med Oral Patol Oral Cir Bucal 18(1):e49–e55
Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R (2011) Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 12, CD008934
van der Reijden WA, Vissink A, Veerman EC, Amerongen AV (1999) Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome. Ann Rheum Dis 58(8):465–474
Sweeney MP, Bagg J, Baxter WP, Aitchison TC (1997) Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients. Palliat Med 11(3):225–232
Blixt-Johansen G, Ek AC, Ganowiak W, Granerus AK, von Schenck H, Unosson M, Wiesel K (1992) Improvement of oral mucosa with mucin containing artificial saliva in geriatric patients. Arch Gerontol Geriatr 14(2):193–201
Duxbury AJ, Thakker NS, Wastell DG (1989) A double-blind cross-over trial of a mucin-containing artificial saliva. Br Dent J 166(4):115–120
Gravenmade EJ, Vissink A (1993) Mucin-containing lozenges in the treatment of intraoral problems associated with Sjögren's syndrome. A double-blind crossover study in 42 patients. Oral Surg Oral Med Oral Pathol 75(4):466–471
Mouly SJ, Orler JB, Tillet Y, Coudert AC, Oberli F, Preshaw P, Bergmann JF (2007) Efficacy of a new oral lubricant solution in the management of psychotropic drug-induced xerostomia: a randomized controlled trial. J Clin Psychopharmacol 27(5):437–443
Ship JA, McCutcheon JA, Spivakovsky S, Kerr AR (2007) Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J Oral Rehabil 34(10):724–732
Aframian DJ, Mizrahi B, Granot I, Domb AJ (2010) Evaluation of a mucoadhesive lipid-based bioerodable tablet compared with Biotene mouthwash for dry mouth relief—a pilot study. Quintessence Int 41(3):e36–e42
Kerr AR, Corby PM, Shah SS, Epler M, Fisch GS, Norman RG (2010) Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc 141(10):1250–1256
Donatsky O, Johnsen T, Holmstrup P, Bertram U (1982) Effect of Saliment on parotid salivary gland secretion and on xerostomia caused by Sjögren's syndrome. Scand J Dent Res 90(2):157–162
Jellema AP, Langendijk H, Bergenhenegouwen L, van der Reijden W, Leemans R, Smeele L, Slotman BJ (2001) The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiother Oncol 59(2):157–160
Persson A, Lingstrom P, Bergdahl M, Claesson R, van Dijken JW (2007) Buffering effect of a prophylactic gel on dental plaque in institutionalised elderly. Gerodontology 24(2):98–104
Regelink G, Vissink A, Reintsema H, Nauta JM (1998) Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int 29(6):383–388
Sreebny LM, Valdini A (1987) Xerostomia. A neglected symptom. Arch Intern Med 147(7):1333–1337
Azodo CC, Ezeja EB, Omoaregba JO, James BO (2012) Oral health of psychiatric patients: the nurse's perspective. Int J Dent Hyg 10(4):245–249
Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB (1999) Sibutramine produces dose-related weight loss. Obes Res 7(2):189–198
Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J (2001) Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 3(2):131–140
Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H (2010) A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 127(1-3):19–30
Kane JM, Yang R, Youakim JM (2012) Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 135(1-3):116–122
Villa A, Abati S (2011) Risk factors and symptoms associated with xerostomia: a cross-sectional study. Aust Dent J 56(3):290–295
Brooks JO 3rd, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, Thase ME (2011) Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the systematic treatment enhancement program for bipolar disorder. J Clin Psychiatry 72(2):240–247
Helenius-Hietala J, Ruokonen H, Gronroos L, Rissanen H, Suominen L, Isoniemi H, Meurman JH (2013) Self-reported oral symptoms and signs in liver transplant recipients and a control population. Liver Transpl 19(2):155–163
Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG (2009) Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry 70(7):1001–1008
Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA (2009) Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 70(11):1540–1547
Wilson K, Mottram P (2004) A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 19(8):754–762
Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(5A Suppl):33–46, discussion 50
Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S (1999) Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 10(5):283–289
Strietzel FP, Martin-Granizo R, Fedele S, Lo Russo L, Mignogna M, Reichart PA, Wolff A (2007) Electrostimulating device in the management of xerostomia. Oral Dis 13(2):206–213
Strietzel FP, Lafaurie GI, Mendoza GR, Alajbeg I, Pejda S, Vuletić L, Mantilla R, Falcão DP, Leal SC, Bezerra AC, Tran SD, Ménard HA, Kimoto S, Pan S, Martín-Granizo RA, Lozano ML, Zunt SL, Krushinski CA, Melilli D, Campisi G, Paderni C, Dolce S, Yepes JF, Lindh L, Koray M, Mumcu G, Elad S, Zeevi I, Barrios BC, López Sánchez RM, Beiski BZ, Wolff A, Konttinen YT (2011) Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum 63(1):180–190
Alajbeg I, Falcão DP, Tran SD, Martín-Granizo R, Lafaurie GI, Matranga D, Pejda S, Vuletić L, Mantilla R, Leal SC, Bezerra AC, Ménard HA, Kimoto S, Pan S, Maniegas L, Krushinski CA, Melilli D, Campisi G, Paderni C, Mendoza GR, Yepes JF, Lindh L, Koray M, Mumcu G, Elad S, Zeevi I, Barrios BC, López Sánchez RM, Lassauzay C, Fromentin O, Beiski BZ, Strietzel FP, Konttinen YT, Wolff A, Zunt SL (2012) Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol 113(6):773–781
Khosravani N, Birkhed D, Ekstrom J (2009) The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study. Eur J Oral Sci 117(3):209–217
Orellana MF, Lagravere MO, Boychuk DG, Major PW, Flores-Mir C (2006) Prevalence of xerostomia in population-based samples: a systematic review. J Public Health Dent 66(2):152–158
Hede B (1995) Oral health in Danish hospitalized psychiatric patients. Community Dent Oral Epidemiol 23(1):44–48
Navazesh M, Brightman VJ, Pogoda JM (1996) Relationship of medical status, medications, and salivary flow rates in adults of different ages. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81(2)):172–176
Nordgarden H, Jensen JL, Arneberg P, Storhaug K (1996) Salivary secretion and oral health in narcolepsy: a pilot study. Spec Care Dent 16(3):128–133
Billings RJ, Proskin HM, Moss ME (1996) Xerostomia and associated factors in a community-dwelling adult population. Community Dent Oral Epidemiol 24(5):312–316
Pajukoski H, Meurman JH, Snellman-Grohn S, Keinanen S, Sulkava R (1997) Salivary flow and composition in elderly patients referred to an acute care geriatric ward. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84(3):265–271
Persson RE, Persson GR, Kiyak HA, Powell LV (1998) Oral health and medical status in dentate low-income older persons. Spec Care Dent 18(2):70–77
Meurman JH, Collin HL, Niskanen L, Toyry J, Alakuijala P, Keinanen S, Uusitupa M (1998) Saliva in non-insulin-dependent diabetic patients and control subjects: the role of the autonomic nervous system. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86(1):69–76
Moore PA, Guggenheimer J, Etzel KR, Weyant RJ, Orchard T (2001) Type 1 diabetes mellitus, xerostomia, and salivary flow rates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92(3):281–291
Last Pollak M, Eliav E, Glick Z, Zusman SP (2002) Saliva secretion and oral health in a hospitalized geriatric population in Israel. Refuat Hapeh Vehashinayim 19(3):74–78, 91
Fure S (2003) A ten-year cross-sectional and follow-up study of salivary flow rates and mutans streptococci and lactobacillus counts in elderly Swedish individuals. Oral Health Prev Dent 1(3):185–194
van der Putten GJ, Brand HS, Bots CP, van Nieuw AA (2003) Prevalence of xerostomia and hyposalivation in the nursing home and the relation with number of prescribed medication. Tijdschr Gerontol Geriatr 34(1):30–36
Lin AL, Johnson DA, Stephan KT, Yeh CK (2003) Alteration in salivary function in early HIV infection. J Dent Res 82(9):719–724
Scelza MF, Silva Dde F, Ahiadzro NK, Da Silva LE, Scelza P (2010) The influence of medication on salivary flow of the elderly: preliminary study. Gerodontology 27(4):278–282
Ohara Y, Hirano H, Yoshida H, Suzuki T (2011) Ratio and associated factors of dry mouth among community-dwelling elderly Japanese women. Geriatr Gerontol Int 11(1):83–89
Bagheri H, Schmitt L, Berlan M, Montastruc JL (1997) A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Eur J Clin Pharmacol 52(5):339–342
Hooper P, Tincello DG, Richmond DH (1997) The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study. Br J Urol 80(3):414–416
Gotrick B, Akerman S, Ericson D, Torstenson R, Tobin G (2004) Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults. J Dent Res 83(5):393–397
Masters KJ (2005) Pilocarpine treatment of xerostomia induced by psychoactive medications. Am J Psychiatry 162(5):1023
Papas A, Singh M, Harrington D, Rodriguez S, Ortblad K, de Jager M, Nunn M (2006) Stimulation of salivary flow with a powered toothbrush in a xerostomic population. Spec Care Dent 26(6):241–246
Kharevich O, Shipman B, Goldman BM, Nahon M (2011) Salese to buffer saliva in elderly patients with xerostomia: a pilot study. J Prosthodont 20(2):135–138
Looström H, Akerman S, Ericson D, Tobin G, Götrick B (2011) Tramadol-induced oral dryness and pilocarpine treatment: effects on total protein and IgA. Arch Oral Biol 56(4):395–400
Acknowledgments
Our sponsors, American Academy of Oral Medicine, Biocosmetics, patients of Dr. David Sirois, European Association of Oral Medicine, Johnson and Johnson, The Oral Cancer Foundation, Unilever, and Elsevier are gratefully acknowledged for their unrestricted educational grants to help us hold the 2014 World Workshop on Oral Medicine VI meeting in Orlando.
Compliance with ethical standards
The authors declare that in preparing this manuscript, they have complied with all relevant and known ethical standards.
Conflict of interest
Andy Wolff owns stock in Saliwell Ltd. The other authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 44 kb)
Rights and permissions
About this article
Cite this article
Villa, A., Wolff, A., Aframian, D. et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment. Clin Oral Invest 19, 1563–1580 (2015). https://doi.org/10.1007/s00784-015-1488-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00784-015-1488-2